Consequently, it is hypothesized that the potential harm resulting from prolonged anlotinib use, which excessively inhibits normal islet capillaries, outweighs the benefits of blocking increased blood supply, ultimately leading to abnormal insulin secretion and diabetes development. This evidence concerns the gene INS and diabetes mellitus.